anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine mixture for treating the pediatric membranous nephropathy. The traditional Chinese medicine holds that the pediatric membranous nephropathy belongs to the 'edema' range and relates to the lung, spleen and kidney three-viscera malfunction. Most of the pediatric membranous nephropathy is mainly characterized by insufficiency of both the spleen and the kidney, blood stasis obstructing the collaterals and internal stagnation of fluid-dampness. The operations of treating the root and strengthening the body resistance serve as the principal, and the operations of warming kidney and eliminating damp are assisted on the basis of invigorating spleen, supplementing qi and invigorating the circulation of blood. Therefore, the traditional Chinese medicine mixture for treating the pediatric membranous nephropathy is prepared from the following traditional Chinese medicines of plantain seed, semen coicis, rust-coloured crotalaria herb with root, herba lycopi, the root of bidentate achyranthes, rhizoma sparganii, astragalus mongholicus, boschniakia rossica, herba epimedii, rhizoma polygonati and rhizoma atractylodis, wherein the traditional Chinese medicines have the efficacy on tonifying Qi, lifting yang, removing blood stasis, and inducing diuresis to alleviate edema. The obtained traditional Chinese medicine mixture is taken by patients. According to the clinical test of our hospital, the total effective rate of the traditional Chinese medicine mixture is 93.3%, and a treatment group is obviously superior to a control group on the aspects of lowering cholesterol (CHOL) and urine protein and improving albumin (ALB) and clinic efficiency.
AIMS: This study aims to explore the inhibitory effect of selenium on cervical cancer through suppression of glucose metabolic reprogramming and its underlying mechanisms.
METHODS: Sodium selenite (SS) treated HeLa and SiHa cells were assessed for proliferation using the CCK-8 assay and immunofluorescence. DNA synthesis was measured with the EdU assay. A nude mouse xenograft model evaluated SS's anti-cervical cancer effects. Reactive oxygen species (ROS) and mitochondrial membrane potential were measured using flow cytometry, DCFH-DA, and JC-1 probes, respectively. Apoptosis was detected via Annexin V/PI staining and Western blot. Glucose uptake, lactate production, and ATP generation were determined using 2-NBDG probes and assay kits. The mRNA and protein levels of glycolysis-related genes HK2, GLUT1, and PDK1 were measured using RT-qPCR and Western blot.
KEY FINDINGS: SS inhibited HeLa and SiHa cells viability in a dose- and time-dependent manner. Intraperitoneal injection of SS in nude mice significantly inhibited HeLa cell xenograft growth without evident hepatotoxicity or nephrotoxicity. SS inhibited glucose metabolic reprogramming in cancer cells primarily via ROS-mediated AKT/mTOR/HIF-1α pathway inhibition. Pretreatment with N-acetylcysteine (NAC) or MHY1485 (an mTOR activator) partially reversed the inhibitory effects of SS on glucose metabolic reprogramming, cell proliferation, and migration, as well as its pro-apoptotic effects.
SIGNIFICANCE: SS exhibited anti-cervical cancer effects, likely through the induction of ROS generation and inhibition of glucose metabolic reprogramming in cervical cancer cells, thereby inhibiting cell proliferation and promoting apoptosis. These findings provide new insights into understanding the molecular mechanisms underlying SS for potential new drug development for cervical cancer.
Cohort Description Ten participants (6 Jena/4 Innsbruck) were included, of whom 6 were female and 4 were male. At the start of the study, patients were aged 7-45 years (mean age: 16.55 ± 13.42 years). Results of sweat tests and lung function FEV1 were available only from 8 patients. Lung function at baseline, as obtained from those patients, ranged from 0.96 to 4.07 L (mean FEV1: 99.7 ± 20.3% predicted, median: 103.6% predicted, IQR=20.4% predicted).
PROBLEM TO BE SOLVED: To obtain a dermal external agent having excellent functional characteristic and a dampness keeping property by including a vegetable squalane containing a specific amount of isoparaffin fraction having a specific melting point. SOLUTION: This dermal external agent is obtained by subjecting a vegetable oil (e.g. soybean oil or a germ oil) to hydrogenation and fractionating extraction and contains a vegetable squalane containing >=5 wt.% of isoparaffin fraction having 25-40 deg.C melting point in an amount of preferably 0.01-100 wt.% based on a total weight of the composition. As a use shape of the external agent, e.g. an ointment, a cream, a lotion, a latex, a pack or a cosmetic oil is preferably exemplified. Further, as an oil agent mixed with the objective external agent, a known external base agent, e.g. a silicone oil such as methylphenylpolysiloxane or hydrocarbons such as paraffin can be used other than the squalane.
PURPOSE:To obtain the titled composition, by filling a magnetic fluid containing a ferromagnetic substance dispersed in a fluorocarbon based solvent and oxygen in a pressure-resistant vessel, having magnetic effect, capable of supplying a large volume of oxygen to the skin, activating skin respiration and sustaining the skin of healthy complexion. CONSTITUTION:An aerosol composition, obtained by filling a ferromagnetic fluid containing a ferromagnetic substance, e.g. magnetite, manganese ferrite, etc., having 100Angstrom -10mu particle size dispersed in a fluorocarbon based solvent, e.g. perfluoroparaffin, and compressed gas of oxygen under pressure in a pressure-resistance vessel and capable of spraying the filled liquid from a nozzle. Since the composition utilizes oxygen as a main propellant, the volume of the oxygen supplied to the skin is large and the skin of healthy complexion can be sustained because of magnetic force effect of the magnetic powder. The composition has characteristic satisfying safety, stability, usability, etc., in combi nation as an aerosol composition.
A novel system for cloning and expression of genes in gram-positive bacteria.  The expression system is based on the finding that many gram-positive bacteria sort proteins to their cell surface through cis-acting N-terminal signal sequences and C-terminal anchor regions. In particular, the cell sorting signals of the streptococcal M6 protein, a well-known surface molecule, are used to construct a gram-positive expression system, designated SPEX  (Streptococcal Protein Expression). Expression is achieved by cloning the gene of interest into an appropriate SPEX cassette which is then stably introduced into a bacterial host, such as the human commensal Streptococcus gordonii.  Depending on the SPEX vector used, recombinant proteins can be anchored to the cell wall prior to release by specific endoproteolytic cleavage or secreted into the culture medium during bacterial growth. The use of host bacteria lacking extracellular proteases should protect secreted proteins from proteolytic degradation. Several expression vectors in this system also produce specifically-tagged recombinant proteins which allows for a one-step purification of the resulting product.
PURPOSE: To obtain a non-emulsified type tip overcoat capable of preventing rouge from sticking on e.g. a cup and excellent in the function to improve the color sustainability of rouge, comprising a metallic soap and/or acylated amino acid, a polyhydric alcohol, water, an oil and an alkyl-modified carboxyvinyl polymer. CONSTITUTION: This tip overcoat is obtained by incorporating a total of 0.1-20wt.% of water and an oil (pref. dimethylpolysiloxane) with a total of 0.05-40wt.% of a metallic soap of formula (RCOO)2 M (R is a 10-24C aliphatic hydrocarbon; M is a metal except Na, K, Rb, Cs and Fr) (pref. zinc laurate) and/or an acylated amino acid (pref. lauroyllysine) and 0.025-90wt.% of a polyhydric alcohol (e.g. propylene glycol) and 0.001-1wt.% of an alkyl-modified carboxyvinyl polymer as emulsifier (e.g. an acrylic alkyl ester copolymer).
PURPOSE:To form the nutrient transfusion-contg. bag for aseptic mixing and dosing of an amino acid transfusion and a fat transfusion by housing both transfusions to the respective chambers of the two-chamber bag in such a manner that the total fat weight in the fat transfusion to the total amino acid weight in the amino acid transfusion attains a specific ratio. CONSTITUTION:The nutrient transfusion-contg. bag which is housed with the amino acid transfusion and the fat transfusion in the respective chambers of the two-chamber bag so as to attain 0.5 to 1 ratio of the total fat weight in the fat transfusion to the total amino acid weight in the amino acid transfusion is formed. The two-chamber bag is a soft bag-shaped container made of plastics and the central part thereof is thermally welded separably to a band shape. A transfusion injection port or discharge port is provided to each of the two chambers which are liquidtightly isolated. The amino acid transfusion and the fat transfusion are packed and hermetically sealed respectively in gaseous nitrogen flow in the respective chambers of the two-chamber bag and are then subjected to high-pressure steam sterilization.
A conventional treatment program will be applied to individuals in both groups 5 days a week for 3 weeks. The conventional exercise program will consist of wand exercises, Codman exercises, stretching exercises for all ranges of motion, and TENS (100Hz, 15 minutes). In addition to the conventional treatment program, a mobilization technique with movement will be applied twice a week, with 10 repetitions.
BACKGROUND: Silicone implants are by far the most widely used implant globally for breast augmentation. Despite technological advancements, complications persist, with silicone lymphadenopathy (siliconoma) being a noteworthy concern. This phenomenon has been inadequately addressed in the existing literature.
OBJECTIVES: The aim of this study was to characterize axillary siliconomas and identify potential risk factors to help reduce their occurrence.
METHODS: The authors conducted a retrospective observational cross-sectional study spanning between 2011 and 2021 at the Shamir Assaf Harofeh Medical Center, Israel. Preoperative ultrasound examination was conducted, categorizing patients into those with siliconomas and those without.
RESULTS: A total of 614 women (1209 breasts) met the inclusion criteria. The incidence of siliconomas was 13.6% (165 breasts). In univariate analysis, older age (47 years vs 43 years, P < .001), older implant age (12.2 years vs 11 years, P = .026), ruptured implants (59.4% vs 17.7%, P < .001), subpectoral placement (P = .019), severe capsular contracture, and the use of Mentor implants (Irvine, CA; P = .007) and Poly Implant Prothèse implants (PIP; La Seyne-sur-Mer, France; P = .001) correlated significantly with the presence of siliconomas. In a multivariate analysis, implant rupture (odds ratio [OR] = 6.342), and implant manufacturer-Mentor (OR = 3.047) and PIP (OR = 3.475)-were identified as independent risk factors associated with a higher incidence of siliconomas. Severe capsular contracture was also associated with a higher incidence of siliconomas (OR = 1.65).
CONCLUSIONS: Surgeons should inform candidates about the potential risk of silicone migration. Patients with ruptured implants, significant capsular contracture, and Mentor and PIP implants face an increased risk for developing siliconomas. Closer monitoring for the detection of siliconomas in the axilla for these patients is advisable, and potential prophylactic replacement or removal of implants may be warranted to mitigate siliconoma risk.
Lumbopelvic pain is self-reported pain. It is common complaint for women after labour, and it is found that 25% of newly delivered women experienced low back and pelvic pain. Different interventions have been used to reduce the lumbopelvic pain in general including exercises, drugs, therapies and massage. An increasingly common approach used within physical therapy management are breathing exercises and core stabilization exercises. This study will used to compare the effects of breathing exercises with and without core stability exercise. Pre-assessment will be done using oswestry disability index as subjective measurement and pain pressure algometer as objective measure.
BACKGROUND: Patients diagnosed with pancreatic, biliary tract, and liver cancer often suffer from a progressive loss of muscle mass. Given the considerable functional impairments in these patients, high musculoskeletal weight loads may not be well tolerated by all individuals. The use of blood-flow restricted resistance training (BFR-T) which only requires low training loads may allow for a faster recovery of muscle due to avoidance of high levels of mechanical muscle stress associated with high-load resistance exercise. This study aims to investigate whether BFR-T can prevent or slow down the loss of skeletal muscle mass and enhance the functional capacity and mental health of patients with pancreatic, biliary tract, and liver cancer.
METHODS: The PREV-Ex exercise trial is a multicenter two-armed randomized controlled trial. Patients will be randomized to an exercise program consisting of home-based low-load BFR-T during a combined pre- and postoperative period for a total of 6-10 weeks (prehabilitation and rehabilitation), or to a control group. Protein supplementation will be given to both groups to ensure adequate protein intake. The primary outcomes, skeletal muscle thickness and muscle cross-sectional area, will be assessed by ultrasound. Secondary outcomes include the following: (i) muscle catabolism-related and inflammatory bio-markers (molecular characteristics will be assessed from a vastus lateralis biopsy and blood samples will be obtained from a sub-sample of patients); (ii) patient-reported outcome measures (self-reported fatigue, health-related quality of life, and nutritional status will be assessed through validated questionnaires); (iii) physical fitness/performance/activity (validated tests will be used to evaluate physical function, cardiorespiratory fitness and maximal isometric muscle strength. Physical activity and sedentary behavior (assessed using an activity monitor); (iv) clinical outcomes: hospitalization rates and blood status will be recorded from the patients' medical records; (v) explorative outcomes of patients' experience of the exercise program which will be evaluated using focus group/individual interviews.
DISCUSSION: It is worthwhile to investigate new strategies that have the potential to counteract the deterioration of skeletal muscle mass, muscle function, strength, and physical function, all of which have debilitating consequences for patients with pancreatic, biliary tract, and liver cancer. The expected findings could improve prognosis, help patients stay independent for longer, and possibly reduce treatment-related costs.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05044065. Registered on September 14, 2021.
Subjects randomized to Arm 2 (\~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m\^2 at least 1 hour and no more than 36 hours prior to surgery. They will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
BACKGROUND: Illicit drug toxicity (i.e., overdose) is the leading cause of death in British Columbia (BC) for people aged 10-59. Stimulants are increasingly detected among drug toxicity deaths. As stimulant use and detection in deaths rises, it is important to understand how people who die of stimulant toxicity differ from people who die of opioid toxicity.
METHODS: BC Coroners Service records were retrieved for all people who died of unintentional illicit drug toxicity (accidental or undetermined) between January 1, 2015, and December 31, 2019, whose coroner investigation had concluded and who had an opioid and/or stimulant detected in post-mortem toxicology and identified by the coroner as relevant to the death (N = 3788). BC Chronic Disease Registry definitions were used to identify people with chronic disease. Multinomial regression models were used to examine the relationship between chronic disease diagnoses and drug toxicity death type.
RESULTS: Of the 3788 deaths, 11.1% (N = 422) had stimulants but not opioids deemed relevant to the cause of death (stimulant group), 26.8% (N = 1014) had opioids but not stimulants deemed relevant (opioid group), and 62.1% (N = 2352) had both opioids and stimulants deemed relevant (opioid/stimulant group). People with ischemic heart disease (1.80 (1.14-2.85)) and people with heart failure (2.29 (1.25-4.20)) had approximately twice the odds of being in the stimulant group as compared to the opioid group.
CONCLUSIONS: Findings suggest that people with heart disease who use illicit stimulants face an elevated risk of drug toxicity death. Future research should explore this association and should identify opportunities for targeted interventions to reduce drug toxicity deaths among people with medical comorbidities.
PURPOSE:An enteric coating composition having improved acid resistance, obtained by dispersing fine powder of enteric cellulose derivative having a specific average particle diameter, inorganic fine powder and a plasticizer into an aqueous medium. CONSTITUTION:An enteric coating composition obtained by dispersing fine powder of an enteric cellulose derivative (e.g., cellulose acetate phthalate) having <10mum average particle diameter, inorganic fine powder (e.g., talc) having <10mum average particle diameter, and a plasticizer (e.g., triethyl citrate) in an aqueous medium. A solid agent such as tablet, granule, fine granule, etc. is covered with the enteric coating composition to give an enteric pharmaceutical preparation having extremely improved denseness, and high acid resistance. An amount of enteric coating agent consumed is reduced, and time required for coating operation is shortened. In a ratio of each component used, 5-200pts.wt. inorganic fine powder and >=5pts.wt. plasticizer are preferably used based on 100pts.wt. enteric cellulose derivative.
Atopic Dermatitis (AD) is a chronic inflammatory skin disorder in which the skin becomes extremely itchy and is susceptible to recurrent skin infections. AD is thought to occur from a combination of immunological, genetic, and environmental factors. Individuals with AD are at risk for developing a severe and widely disseminated infection called eczema vaccinatum (EV). EV is caused when the live attenuated vaccinia virus in the vaccine reproduces and spreads throughout the body. Individuals with AD lack certain antimicrobial peptides, specifically cathelicidins.

This trial also includes a sub-study with individuals who have psoriasis. Psoriasis is also an immune-mediated skin disease, and is characterized by scaling skin and inflammation (pain, swelling, heat, and redness). Most psoriasis cause patches of thick, red skin with silvery scales. These patches can itch or feel sore. This sub-study will provide additional information on psoriatic responses to oral vitamin D. (Originally listed separately as ADVN-CATH-03-01).
Patients undergo radiation therapy for 10 fractions over 2 weeks, and receive ONC201 PO daily on days 1, 2, 8, and 9. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. Beginning 7 days from last pre-surgery dose of ONC201, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
In clinic, administration of oral carbohydrate 2-3 hours before surgery has been widely applied in elective colorectal surgery. However, no direct evidence has been showed that whether it is safe to do so in gastric cancer patients who are fit for elective radical gastric resection.

This study aims to discuss the impact and safety of oral administration of 5% glucose solution 250ml 2-3 hours before elective gastric cancer surgery. It is an equivalence study, which refers to a single-center, prospective, single blind, and randomized controlled study design. Eighty-eight patients with gastric adenocarcinoma are going to be enrolled in the study, who will be allocated into control or treatment group. Patients in control group follow the traditional routine of 6-8 hours preoperative fasting, while those in the treatment group will orally intake 250ml 5% glucose solution 2-3 hours before surgery. The primary end-point is the preoperative gastric residual volume. The secondary end-points include preoperative PH of gastric fluid, assessment of perioperative psychosomatic conditions, rate of perioperative complications, level of insulin sensitivity, recovery of bowel function, and the length of hospital stay, etc.
In an open-label QTc study in patients with schizophrenia or schizoaffective disorder (n=160), FANAPT was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily. The effect of FANAPT on the QT interval was augmented by the presence of CYP450 2D6 or 3A4 metabolic inhibition (paroxetine 20 mg once daily and ketoconazole 200 mg twice daily, respectively). Under conditions of metabolic inhibition for both 2D6 and 3A4, FANAPT 12 mg twice daily was associated with a mean QTcF increase from baseline of about 19 msec.

No cases of torsade de pointes or other severe cardiac arrhythmias were observed during the pre-marketing clinical program.

The use of FANAPT should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). FANAPT should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Certain circumstances may increase the risk of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval; (5) recent acute myocardial infarction; and/or (6) uncompensated heart failure. 

Caution is warranted when prescribing FANAPT with drugs that inhibit FANAPT metabolism [see Drug Interactions (7.1)], and in patients with reduced activity of CYP2D6 [see Clinical Pharmacology (12.3)].

It is recommended that patients being considered for FANAPT treatment who are at risk for significant electrolyte disturbances have baseline serum potassium and magnesium measurements with periodic monitoring. Hypokalemia (and/or hypomagnesemia) may increase the risk of QT prolongation and arrhythmia. FANAPT should be avoided in patients with histories of significant cardiovascular illness, e.g., QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia. FANAPT should be discontinued in patients who are found to have persistent QTc measurements >500 msec.

If patients taking FANAPT experience symptoms that could indicate the occurrence of cardiac arrhythmias, e.g., dizziness, palpitations, or syncope, the prescriber should initiate further evaluation, including cardiac monitoring.